Prime Medicine Q4 GAAP EPS $(0.72) Misses $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Prime Medicine (NASDAQ:PRME) reported Q4 adjusted EPS of $(0.72), missing the consensus estimate of $(0.51) by 41.18%, marking a 28.57% increase in losses from the same period last year.
March 01, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Prime Medicine reported a significant miss in Q4 earnings, with adjusted EPS of $(0.72) against an expected $(0.51), indicating a 28.57% increase in losses year-over-year.
The significant miss in earnings expectations and the increase in losses year-over-year are likely to negatively impact investor sentiment and could lead to a short-term decrease in PRME's stock price. The magnitude of the miss and the comparison to last year's performance are critical factors that investors will consider.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100